HLB "Lenvatinib, Combination Clinical Trial in Locally Advanced Gastric Cancer Patients Shows 'Complete Remission'"

[Asia Economy Reporter Hyunseok Yoo] HL Biotech announced on the 12th that complete remission was observed in patients with locally advanced gastric cancer following clinical research conducted in China on rivoceranib (Chinese name Apatinib) combined with multiple cytotoxic anticancer drugs.

According to data released on the 10th by the research team at Zhengzhou University Cancer Hospital in China, the clinical trial involving 75 patients with locally advanced gastric cancer (LAGC) showed that combination therapy of the standard treatment FLOT regimen (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) and rivoceranib resulted in 4 cases (12.9%) of complete remission, an ORR (objective response rate) of 80.65%, and a DCR (disease control rate) of 93.55%. This demonstrated superior efficacy compared to the control group treated with FLOT regimen alone, which showed 1 case (2.27%) of complete remission, an ORR of 50.00%, and a DCR of 88.64%.

Rivoceranib is a targeted anticancer drug developed by HL Biotech with global rights, targeting vascular endothelial growth factor receptor 2 (VEGFR-2). It excels at inhibiting neovascularization in cancer tissues and proliferation of cancer cells while normalizing immune cells, making it highly versatile across various cancer types. Since its launch in China in 2015 as a gastric cancer treatment (brand name Aitan), it has generated sales exceeding 1 trillion KRW over seven years.

This content was produced with the assistance of AI translation services.